

1614

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: HENDERSON
SERIAL NO.: 09/845,741
FILED: MAY 1, 2001
TITLE: USE OF MEDIUM CHAIN TRIGLYCERIDES
FOR THE TREATMENT AND PREVENTION OF
ALZHEIMER'S DISEASE AND OTHER
DISEASES RESULTING FROM REDUCED
NEURONAL METABOLISM

} EXAMINER:
} ART UNIT: 1614
} CONFIRMATION NO: 3451

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant calls the Examiner's attention to the patents and publications listed on the attached Form PTO-1449, copies enclosed, which may be material to examination of the above identified application.

TIME OF TRANSMITTAL

This Information Disclosure Statement is being submitted under 37 CFR § 1.97(c). This Statement is filed after three months from the filing date of the national application, after three months from the date of entry into national stage under 37 CFR § 1.491, after the mailing of a first Office Action on the merits, or after the mailing of a first Office Action after the filing of a requested for continued examination under 37 CFR § 1.114, but before the mailing date of any of:

- (a) a final action under 37 CFR § 1.113;
- (b) a notice of allowance under 37 CFR § 1.311; or
- (c) an action that otherwise closes prosecution in the application.

Certification under 37 CFR § 1.97(e)(1)

The undersigned hereby certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent

37 CFR 1.8

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on 3/19/04

Signature:

Name: Tasha L. Cove

Tasha L. Cove


office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

No fee is believed to be due in this instance. However, the undersigned hereby authorizes the charging of any fees associated with this document to Deposit Account No. 19-5117.


The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. This listed patents and publications are believed of interest herein and consideration and citation of as interest by Examiner is respectfully requested.

Respectfully submitted,

Date: March 19, 2004


Darla G. Yoerg, #48,053
Swanson & Bratschun, L.L.C.
1745 Shea Center Drive, Suite 330
Highlands Ranch, Colorado 80129
Telephone: (303) 268-0066
Facsimile: (303) 268-0065

cc: S. Orndorff
S:\CLIENT FOLDERS\ACCERA\ACC01\IDS3.DOC



**U.S. DEPARTMENT OF
COMMERCE PATENT
AND TRADEMARK
OFFICE**

List of Information Cited by Applicant

Page 1 of 1

ATTY. DOCKET NO.

ACC.01

SERIAL NO.

09/845,741

APPLICANT

HENDERSON

FILING DATE

MAY 1, 2001

GROUP

1614

U.S. PATENT DOCUMENTS

EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB- CLS	FILE DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						

FOREIGN PATENT DOCUMENTS

EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS	TRANS ?
	AO						
	AP						
	AQ						
	AR						
	AS						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AT	COX ET AL. (1998) J OF PEDIATRICS 133(2):247-253
	AO	THAL ET AL. (1996) NEUROLOGY 47(3):705-711
	AV	KASHIWAYA ET AL. (2000) PROC NATL ACAD SCI USA 97(10):5440-5444
	AW	
	AX	
	AY	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.